4.7 Article

A myeloid tumor suppressor role for NOL3

期刊

JOURNAL OF EXPERIMENTAL MEDICINE
卷 214, 期 3, 页码 753-771

出版社

ROCKEFELLER UNIV PRESS
DOI: 10.1084/jem.20162089

关键词

-

资金

  1. NYSTEM grant [C029154]
  2. National Institutes of Health (NIH) [R01CA166429, R01CA196973]
  3. MSTP training grant [T32GM007288]
  4. National Heart, Lung, and Blood Institute Fellowship [F30HL122085]
  5. NIH Cellular and Molecular Biology and Genetics Training Grant [T32GM007491]
  6. Dr. Gerald and Myra Dorros Chair in Cardiovascular Disease

向作者/读者索取更多资源

Despite the identification of several oncogenic driver mutations leading to constitutive JAK-STAT activation, the cellular and molecular biology of myeloproliferative neoplasms (MPN) remains incompletely understood. Recent discoveries have identified underlying disease-modifying molecular aberrations contributing to disease initiation and progression. Here, we report that deletion of Nol3 (Nucleolar protein 3) in mice leads to an MPN resembling primary myelofibrosis (PMF). Nol3(-/-) MPN mice harbor an expanded Thy1(+)LSK stem cell population exhibiting increased cell cycling and a myelomonocytic differentiation bias. Molecularly, this phenotype is mediated by Nol3(-/-) -induced JAK-STAT activation and downstream activation of cyclin-depen-dent kinase 6 (Cdk6) and Myc. Nol3(-/-) MPN Thy1(+)LSK cells share significant molecular similarities with primary CD34(+) cells from PMF patients. NOL3 levels are decreased in CD34(+) cells from PMF patients, and the NOL3 locus is deleted in a subset of patients with myeloid malignancies. Our results reveal a novel genetic PMF-like mouse model and identify a tumor suppressor role for NOL3 in the pathogenesis of myeloid malignancies.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.7
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据